Welcome to our story

Pancreatic Cancer 

64,000 new diagnoses and 55,500 deaths annually.  

Chemotherapy and targeted therapy have limited success mainly because pancreatic stem cells are particularly resistant to treatment. These issue lead to an average 5-year survival rate of only 12%. 

Combination Immuno-Oncology Treatment & Toxicity 

IO therapy such as check point inhibitors has been transformational in a wide variety of cancers. They prevent cancer cells from blocking the immune system resulting in cancer cell death. IO therapy may fail due to high IL-17 signaling that can lead to T cell exhaustion. TH17 cells are implicated in autoimmunity and IO toxicities. Combination IO therapy has high rate of serious side effects which can result in limited treatment duration or even death 

XT-0528 is an oral small molecule ROR𝛾T inverse agonist. XT-0528 expression is increased in human pancreatic cancer cells and blockade limits tumor growth in both cellular and mouse models. 

Since XT-0528 reduces IL-17 and inflammatory signaling it may enable IO therapies to work more effectively while lowering toxicity and serious side effects.  The blockade of ROR𝛾T has shown to prevent toxicity of colitis in a recognized animal model.  

The benefits of XT-0528 may include 

• Primary action against Pancreatic Cancer Stem Cells 
• Enhanced immunotherapy through more tolerable cycles 
• Lower toxicity and prevent/decrease side effects 
• Improve response & Increase IO adoption 
• Decrease healthcare costs